Development of conditional-siRNA programmable riboswitch for targeting adverse cardiac remodeling

Heart failure (HF) remains a significant healthcare burden, with an unmet need for novel therapies to target the preceding pathological hypertrophy in HF patients. Here we report the development of novel conditional-siRNA (Cond-siRNA) constructs that are selectively activated by disease-specific RNA...

Descripció completa

Dades bibliogràfiques

Autors principals:	Priyanka Gokulnath, Ane M. Salvador, Caleb Graham, Si-ping Han, Guoping Li, Ramaswamy Kannappan, Christopher Azzam, Michail Spanos, Lisa Scherer, Palaniappan Sethu, John Rossi, William A. Goddard, III, Saumya Das
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-09-01
Col·lecció:	Molecular Therapy: Nucleic Acids
Matèries:	MT: Oligonucleotides: Therapies and Applications siRNA RNA therapeutics cardiac hypertrophy heart-on-chip model riboswitch
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2162253125002215
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!